APOE and atherosclerosis: To determine whether saracatinib can exert antiatherosclerotic and anti-inflammatory effects and work as well as the gold-standard atorvastatin at reducing atherosclerosis progression in vivo, we fed apolipoprotein E-deficient (Apoe−/−; 6-week-old) mice a Western diet (WD) for 16 weeks with or without various dosages of saracatinib and/or atorvastatin admixed into their food (Fig. 7).